Current Report Filing (8-k)
January 13 2022 - 09:01AM
Edgar (US Regulatory)
false 0000876378 0000876378 2022-01-13
2022-01-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 13, 2022
Date of Report (date of earliest event reported)
_________________
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
_________________
Delaware
(State or other jurisdiction of
incorporation or organization)
|
0-19437
(Commission
File Number)
|
11-2962080
(I.R.S. Employer
Identification Number)
|
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
_________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock
$0.001 par value per share
|
|
ASXC
|
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01
Regulation FD Disclosure
On January 13, 2022, Asensus Surgical, Inc. (the “Company”) is
making a corporate presentation that provides a current overview
about the Company to participants at the 40th Annual
J.P. Morgan Healthcare Conference. The information provided during
such corporate presentation is furnished as Exhibit 99.1 to this
Form 8-K.
The information in this Item 7.01 and the Exhibit 99.1 attached
hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, except as shall
be expressly set forth by specific reference in such
filing.
Item 9.01
Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
ASENSUS SURGICAL,
INC.
|
|
|
|
|
Date: January 13,
2022
|
/s/ Shameze
Rampertab
|
|
|
Shameze
Rampertab
|
|
|
Executive Vice
President and Chief Financial Officer
|
|
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Feb 2023 to Mar 2023
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2022 to Mar 2023